Experience with low-density lipoprotein apheresis by polyclonal and monoclonal anti-apolipoprotein B antibodies and by dextran sulfate cellulose.
Riesen
W F
WF
Institute for Clinical Chemical and Hematology, Kantonsspital, St. Gallen, Switzerland.
D000906:Antibodies / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D001055:Apolipoproteins B / Q000276:immunology; D001781:Blood Component Removal; D002482:Cellulose / Q000276:immunology; D002784:Cholesterol / Q000097:blood; D016264:Dextran Sulfate / Q000276:immunology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000628:therapy; D007163:Immunosorbent Techniques; D008077:Lipoproteins, LDL / Q000276:immunology; D014280:Triglycerides / Q000097:blood
D000906:Antibodies; D000911:Antibodies, Monoclonal; D001055:Apolipoproteins B; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002482:Cellulose; D016264:Dextran Sulfate; D002784:Cholesterol